quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:05:29·25d
SECFiling
PDS Biotechnology Corporation logo

PDS Biotechnology Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

PDSB· PDS Biotechnology Corporation
Health Care
Original source

Companies

  • PDSB
    PDS Biotechnology Corporation
    Health Care

Recent analyst ratings

  • Nov 1UpdateB. Riley Securities$10.00
  • Aug 12UpdateHC Wainwright & Co.$15.00
  • Jun 28UpdateCantor Fitzgerald$25.00

Related

  • PR9d
    PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
  • SEC9d
    PDS Biotechnology Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • SEC24d
    SEC Form 10-K filed by PDS Biotechnology Corporation
  • PR25d
    PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement
  • PR30d
    PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results
  • INSIDER51d
    SEC Form 4 filed by Director Glover Stephen C.
  • INSIDER51d
    SEC Form 4 filed by President/CEO Bedu-Addo Frank
  • INSIDER51d
    SEC Form 4 filed by Chief Financial Officer Boesgaard Lars
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022